Stuart Jamieson (CPI Biologics)

article

What are the challenges in developing and delivering lipid nanoparticle mRNA-based vaccines?

29 June 2021 | By Andrew Bright (CPI), Stuart Jamieson (CPI Biologics)

In response to the COVID-19 pandemic caused by the SARS-CoV-2 virus, the emergence of RNA vaccine technology has enabled rapid development of critical vaccines. Traditional vaccine production methods makerapid development challenging, requiring cell line production of viral proteins and laborious purification development, which requires extensive effort and long timelines. RNA…

article

Innovations in analytical science: development of rapid, high-throughput glycoanalytics for biopharmaceuticals

16 December 2020 | By Cristina Blood (CPI Biologics), Lewis Wharram (CPI Biologics), Martin Hulley (Allergan Biologics Ltd), Phil Widdowson (Allergan Biologics Ltd), Robert Dunne (GlycoSeLect Ltd), Roisin Thompson (CPI Biologics), Spyridon Gerontas (Allergan Biologics Ltd), Stuart Jamieson (CPI Biologics), Victoria Smith (CPI Biologics)

Researchers have developed a novel high-throughput method for the detection of glycans in purified biopharmaceutical samples. In this article, Victoria Smith, Lewis Wharram and Stuart Jamieson discuss their innovative approach and the implications for safety and potency assurance in biopharmaceuticals.